PALO ALTO, Calif.--(BUSINESS WIRE)--StemCells, Inc. (NASDAQ:STEM) today announced that Martin McGlynn, the Company’s President and Chief Executive Officer, will present at the 11th Annual BIO CEO & Investor Conference which is being held February 9-10, 2009 at the Waldorf-Astoria in New York. Mr. McGlynn, who is scheduled to speak on Monday, February 9th at 9:00 a.m., Eastern Standard Time, plans to report on the status of the Company’s CNS and Liver Programs, including its Phase I clinical trial in neuronal ceroid lipofuscinosis and its recently approved IND (Investigational New Drug application) for a clinical trial in Pelizeaus-Merzbacher Disease.
